Biotricity Inc. (BTCY) stock
BTCYOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31
$0.05+0.00 (+8.70%)
Close on Oct 19, 2026Market cap $1.15MP/E –Yield –
Biotricity revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Biotricity's revenue for the twelve months ending Jun 30, 2026 was $16.40M, up 13.4% year over year. For fiscal 2026 it was $16.00M, up 16.0% from the year before. The highest annual figure on record is $16.00M in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $16.00M | +16.0% |
| FY2025 | Mar 31, 2025 | $13.79M | +14.3% |
| FY2024 | Mar 31, 2024 | $12.06M | +25.2% |
| FY2023 | Mar 31, 2023 | $9.64M | +26.0% |
| FY2022 | Mar 31, 2022 | $7.65M | +126.0% |
| FY2021 | Mar 31, 2021 | $3.38M | +138.7% |
| FY2020 | Mar 31, 2020 | $1.42M | +256.0% |
| FY2019 | Mar 31, 2019 | $398.20K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $4.28M | +10.4% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $4.25M | +14.8% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $3.99M | +10.2% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $3.89M | +18.9% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $3.87M | +21.0% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $3.70M | +16.5% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $3.62M | +21.7% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $3.27M | +13.0% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $3.20M | +6.0% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $3.18M | +15.9% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $2.97M | +20.9% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $2.89M | +34.6% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $3.02M | +56.5% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $2.74M | +51.7% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $2.46M | +39.4% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $2.15M | +81.0% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $1.93M | +92.8% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $1.81M | +142.7% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $1.76M | +290.4% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $1.19M | +227.1% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $1.00M | +162.2% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $744.59K | +115.3% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $451.90K | +38.2% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $362.92K | +64.9% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $381.90K | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $345.91K | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $327.00K | – |
| Q1 FY2019CQ2 2018 | Dec 31, 2018 | $220.06K | – |
See a number that looks wrong?